Cross - #neutralization of #Influenza A by #SARS-CoV-2 specific neutralizing #antibodies and polyclonal #plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A? Heliyon, https://www.cell.com/heliyon/fulltext/S2405-8440(24)16669-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2405844024166698%3Fshowall%3Dtrue

This #investigation revealed that neutralizing antibodies of #delta #variant cross-reacted with the Influenza A virus, which might protect against influenza viruses and reduce and shift the seasonal influenza circulation during the COVID-19 pandemic.

#Neutralization of #SARS-CoV-2 #KP1, #KP11, #KP2 and #KP3 by #human and murine #sera

Source: npj Vaccines, AbstractWe report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization…

https://etidioh.wordpress.com/2024/11/11/neutralization-of-sars-cov-2-kp1-kp11-kp2-and-kp3-by-human-and-murine-sera/

#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1

We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

#SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R

Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.